- Evaluate efficacy and safety data from clinical trials evaluating TROP2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
- Integrate TROP2–targeted ADCs into individualized treatment plans for patients with TNBC
- Discuss disparities in care among diverse populations of patients with TNBC, including potential root causes and regional differences in attitudes and practice patterns
Featured IBC West Symposia
Overview
Triple-negative breast cancer (TNBC) remains a cancer of significant unmet need, with limited treatment options beyond systemic chemotherapy. Recently, TROP2 has emerged as a target of interest, and antibody-drug conjugates (ADCs) targeting TROP2 can provide substantial clinical benefit to patients with TNBC. However, the incorporation of treatments exploiting TROP2 requires navigation of practical challenges related to treatment and management of adverse events.
In this dynamic tumor board program, expert faculty will address these issues and guide structured discussions on the latest evidence surrounding the role of TROP2-targeted therapies and ADC sequencing strategies for the treatment of TNBC. Through education, clinicians will be better equipped to provide quality care and optimize outcomes for their patients with TNBC. This program will take place in conjunction with the 24th Annual International Congress on the Future of Breast Cancer® – East and West conferences and will feature an in-person session live-streamed for a wider audience and for those unable to attend in person.
Learning Objectives